MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ROCKWELL, M.
Right arrow Articles by MAGUIRE, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ROCKWELL, M.
Right arrow Articles by MAGUIRE, M. H.

Molecular Pharmacology, Vol 2, 574-584, Copyright © 1966 by the American Society for Pharmacology and Experimental Therapeutics

Studies on Adenosine Deaminase

I. Purification and Properties of Ox Heart Adenosine Deaminase

MARGARET ROCKWELL 1 and M. HELEN MAGUIRE 1

1 Smith Kline and French Institute, Department of Pharmacology, University of Sydney, Australia

Adenosine deaminase (adenosine aminohydrolase, EC 3.5.4.4.) has been purified 1060-fold from ox heart muscle. Adenosine, 2-deoxyadenosine, 2,6-diaminopurineriboside, 6-hydroxylaminopurineriboside and 6-chloropurine riboside are substrates of the enzyme, and adenosine and deoxyadenosine both exhibit substrate inhibition at concentrations of substrate about five times the Michaelis value. A number of 2-substituted adenosine analogs that have vasodilator properties have been shown to inhibit the enzyme competitively, and the cardiac glycoside ouabain has been found to be a competitive inhibitor. N6-methylation of adenosine and of several 2-substituted adenosines gave inhibitors with increased affinity for the enzyme active site; however, N6-dimethyl adenosine and adenosine-1-N-oxide inhibited noncompetitively. The relationship between the structure of the cardioactive adenosine analogs and their affinity for adenosine deaminase is considered.

Note:
ACKNOWLEDGMENT We are indebted to Mr. Frank Michal of this Institute for permission to include some of his unpublished pharmacologic data.

Submitted on July 18, 1966







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1966 by the American Society for Pharmacology and Experimental Therapeutics